NZ774030A - Anti-human cd45rc antibodies and uses thereof - Google Patents

Anti-human cd45rc antibodies and uses thereof

Info

Publication number
NZ774030A
NZ774030A NZ774030A NZ77403019A NZ774030A NZ 774030 A NZ774030 A NZ 774030A NZ 774030 A NZ774030 A NZ 774030A NZ 77403019 A NZ77403019 A NZ 77403019A NZ 774030 A NZ774030 A NZ 774030A
Authority
NZ
New Zealand
Prior art keywords
same
diseases
human cd45rc
antibodies
cd45rc antibodies
Prior art date
Application number
NZ774030A
Other languages
English (en)
Inventor
Carole Guillonneau
Ignacio Anegon
Original Assignee
Inst Nat Sante Rech Med
Ct Hospitalier Universitaire Nantes
Univ Nantes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Ct Hospitalier Universitaire Nantes, Univ Nantes filed Critical Inst Nat Sante Rech Med
Publication of NZ774030A publication Critical patent/NZ774030A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ774030A 2018-09-21 2019-09-20 Anti-human cd45rc antibodies and uses thereof NZ774030A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18306230.6A EP3626265A1 (en) 2018-09-21 2018-09-21 Anti-human cd45rc antibodies and uses thereof
PCT/EP2019/075374 WO2020058495A1 (en) 2018-09-21 2019-09-20 Anti-human cd45rc antibodies and uses thereof

Publications (1)

Publication Number Publication Date
NZ774030A true NZ774030A (en) 2026-03-27

Family

ID=63713787

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ774030A NZ774030A (en) 2018-09-21 2019-09-20 Anti-human cd45rc antibodies and uses thereof

Country Status (13)

Country Link
US (2) US12168694B2 (cg-RX-API-DMAC7.html)
EP (2) EP3626265A1 (cg-RX-API-DMAC7.html)
JP (2) JP7796531B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210070303A (cg-RX-API-DMAC7.html)
CN (1) CN113164595A (cg-RX-API-DMAC7.html)
AU (1) AU2019343746C1 (cg-RX-API-DMAC7.html)
BR (1) BR112021005276A2 (cg-RX-API-DMAC7.html)
CA (1) CA3113562A1 (cg-RX-API-DMAC7.html)
IL (1) IL281608B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021003281A (cg-RX-API-DMAC7.html)
NZ (1) NZ774030A (cg-RX-API-DMAC7.html)
SG (1) SG11202102659RA (cg-RX-API-DMAC7.html)
WO (1) WO2020058495A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3626265A1 (en) * 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human cd45rc antibodies and uses thereof
US20230147657A1 (en) * 2020-03-20 2023-05-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Chimeric antigen receptor specific for human cd45rc and uses thereof
PL4401842T3 (pl) * 2021-09-16 2025-11-24 Aboleris Pharma Domeny wiążące przeciwko ludzkiemu CD45RC i ich zastosowania
CA3240875A1 (en) 2021-12-23 2023-06-29 Stefanie Urlinger Discernible cell surface protein variants of cd45 for use in cell therapy
EP4637928A1 (en) 2022-12-23 2025-10-29 Cimeio Therapeutics AG Antibodies targeting cd45

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US7837980B2 (en) 2004-03-02 2010-11-23 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
JP2008519863A (ja) 2004-11-12 2008-06-12 シアトル ジェネティクス インコーポレイティッド N末端にアミノ安息香酸単位を有するオーリスタチン
EP1898529A1 (en) 2005-06-28 2008-03-12 Pioneer Corporation Broadcast receiving apparatus, interference detecting apparatus and interference detecting method
HUE035853T2 (en) 2005-07-18 2018-05-28 Seattle Genetics Inc Beta-glucuronide-linker-drug conjugates
AU2006294644A1 (en) 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
ES2642787T3 (es) 2005-10-21 2017-11-20 Lfb Usa, Inc. Anticuerpos con actividad de citotoxicidad celular dependiente de anticuerpos mejorada, métodos para su producción y uso
KR101703299B1 (ko) 2007-06-01 2017-02-06 오픈 모노클로날 테크놀로지, 인코포레이티드 내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물
US20120258496A1 (en) 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
FR3003171B1 (fr) 2013-03-15 2015-04-10 Lab Francais Du Fractionnement Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire
US20170226209A1 (en) * 2014-08-01 2017-08-10 INSERM (Institut National de la Santé et de la Recherche Médicale) An anti-cd45rc antibody for use as drug
GB201601073D0 (en) * 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
EP3626265A1 (en) * 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human cd45rc antibodies and uses thereof

Also Published As

Publication number Publication date
BR112021005276A2 (pt) 2021-07-13
IL281608B1 (en) 2025-12-01
US20220033500A1 (en) 2022-02-03
WO2020058495A1 (en) 2020-03-26
MX2021003281A (es) 2021-08-11
AU2019343746C1 (en) 2026-04-02
SG11202102659RA (en) 2021-04-29
JP7796531B2 (ja) 2026-01-09
US20250122300A1 (en) 2025-04-17
CA3113562A1 (en) 2020-03-26
AU2019343746A1 (en) 2021-04-15
CN113164595A (zh) 2021-07-23
IL281608B2 (en) 2026-04-01
IL281608A (en) 2021-05-31
AU2019343746B2 (en) 2025-12-04
JP2022502024A (ja) 2022-01-11
KR20210070303A (ko) 2021-06-14
JP2025164963A (ja) 2025-10-31
EP3852802A1 (en) 2021-07-28
US12168694B2 (en) 2024-12-17
EP3626265A1 (en) 2020-03-25

Similar Documents

Publication Publication Date Title
ZA202308021B (en) Anti-ctla4 antibodies and methods of making and using the same
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
PH12023550266A1 (en) Anti-ceacam5 antibodies and conjugates and uses thereof
EP4566621A3 (en) Dll3/cd3 binding proteins for the treatment of cancer
MX2025009223A (es) Agentes de union a clec9a y su uso
MX2023000781A (es) Anticuerpos monoclonales anti-cd47 humanizados, de raton, o quimericos.
ZA202202363B (en) Antibodies against ilt2 and use thereof
MX2021006615A (es) Proteinas de union triespecificas y metodos de uso.
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
MX2019009255A (es) Proteínas quiméricas dirigidas y sus usos.
MY203553A (en) Novel engineered t cell receptors and immune therapy using the same
MX2017010793A (es) Terapeuticos de anticuerpo que ligan cd137.
MX2019001920A (es) Arn la terapia contra el cancer.
MD4716B1 (ro) Anticorpi anti-LAG3 şi fragmente de legare a antigenului
NZ759601A (en) Aggrecan binding immunoglobulins
WO2019112347A3 (ko) 악성 b 세포를 특이적으로 인지하는 항체 또는 그의 항원 결합 단편, 이를 포함하는 키메라 항원 수용체 및 이의 용도
MY196631A (en) Antibody Agents Specific for Human Cd19 and uses Thereof
MX2023001776A (es) Anticuerpos contra ilt2 y uso de los mismos.
ZA202212133B (en) Anti-cd200r1 antibodies and methods of use thereof
MX2022011683A (es) Receptor de antigeno quimerico especifico para cd45rc humano y usos del mismo.
MX2021003281A (es) Anticuerpos anti-cd45rc humanos y usos de los mismos.
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
ZA202110285B (en) Antibodies and methods of use
SG11201903800XA (en) ANTIBODY BINDING SPECIFICALLY TO CD66c AND USE THEREOF
MX2022015966A (es) Anticuerpos y metodos para tratar enfermedades asociadas a claudina.